Celanese debuts controlled-release excipients

Celanese has unveiled VitalDose, an excipient for controlled-release drugs. The ingredients allow drugmakers to customize API release properties.

VitalDose is intended for transdermal, subcutaneous implant, and mucosal insert dosage forms, the company says. The specialty materials maker is targeting the opportunity it sees in new routes of administration for existing drugs as a means of thwarting generics competition. Enhanced bioavailability of poorly soluble drugs is another application.

The new excipients are based on ethylene vinyl acetate polymers.

- here's the Celanese announcement

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.